| Document |
Document Title |
|
WO/2006/004180A1 |
A method for producing an optically active cyclopropanecarboxylate compound represented by the following formula (5): (wherein R6, R7, R8, R9 and R10 are as defined below) is disclosed which is characterized by reacting an olefin represe...
|
|
WO/2006/000323A1 |
The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I), wherein R1 to R6, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These ...
|
|
WO/2005/123702A1 |
Disclosed are (2S)-2-&lcub 1-[(1S)-1-Isobutoxycarbonyl-2-(5-phenyl-oxazol-2-yl)-ethylca
rbamoyl]-cyclopentylmethyl&rcub -4-methoxy-butyric, Potassium-(2S)-2-&lcub 1-[(1S)-1-Isobutoxycarbonyl-2-(5-phenyl-oxazol-2-yl)-ethylca
rbamoyl]-cycl...
|
|
WO/2005/123703A2 |
The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful f...
|
|
WO/2005/123050A2 |
The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): (I) [INSE...
|
|
WO/2005/120515A2 |
Disclosed herein are carbonyl compounds of having the structural formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not l...
|
|
WO/2005/121130A2 |
This invention relates to compounds of the Formula (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-&agr or combinati...
|
|
WO/2005/117817A1 |
The invention relates to an agent for dying keratin fibers, particularly human hair, containing, in a cosmetically acceptable carrier and in the form of coupler components, at least one m-phenylene diamine derivative of general formula (...
|
|
WO/2005/118561A1 |
The present invention relates to benzoxazolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, in the treatment of movement disorders, in particular in Parkinson's ...
|
|
WO/2005/118511A2 |
Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are biphenyls and rela...
|
|
WO/2005/118543A1 |
A compound represented by the general formula (I): [wherein A represents optionally substituted amino or a group represented by the formula (II) (wherein ring A1 represents an optionally substituted nitrogenous heterocyclic group); D rep...
|
|
WO/2005/115148A1 |
Compounds of formula (I) are described: along with compositions thereof, methods of use thereof (particularly as fungicides), and methods of making the same.
|
|
WO/2005/116018A1 |
The invention provides compounds of the general formula (I), racemic mixtures, optical isomers, pharmaceutically acceptable salts, solvates and pharmaceutical compositions thereof. The definitions of substituents in the general formula (...
|
|
WO/2005/116016A1 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated R...
|
|
WO/2005/115999A1 |
The present invention relates to compounds of general formula I, and racemic mixtures, optically active isomers, pharmaceutically acceptable salts or solvates thereof, in which the definition of each radical is described in the claims, a...
|
|
WO/2005/115998A1 |
The invention provides compounds of the general formula (I), racemic mixtures, optical isomers, pharmaceutically acceptable salts, solvates and pharmaceutical compositions thereof. The definitions of substituents in the general formula (...
|
|
WO/2005/115983A1 |
Aryl sulfonamide and sulfonyl compounds of formula (I) as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
|
|
WO/2005/113523A1 |
Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are benzoxazoles and r...
|
|
WO/2005/113520A1 |
The present invention relates to trifluorphenyl oxazolidinones of formula (I) and to the process for the synthesis of the same. The compounds of the present invention are useful antimicrobial agents, effective against a number of human a...
|
|
WO/2005/113490A1 |
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfone-c...
|
|
WO/2005/113522A1 |
In accordance with the present invention, compounds of formula (I) that inhibit Type III protein secretion have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Ty...
|
|
WO/2005/113542A2 |
The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer’s Disease. Compounds of particular interest are defined by Formula (I), wherein R4, R5, R6, R7 and R8 are as...
|
|
WO/2005/112945A2 |
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among man...
|
|
WO/2005/113521A1 |
An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided.
|
|
WO/2005/113558A2 |
A simple and effective stereocontrolled synthesis of salinosporamide A (1) has been developed which follows the pathway outlined in the Figure. The process, the first total synthesis of salinosporamide A, is capable of providing the comp...
|
|
WO/2005/110990A1 |
The invention relates to the compounds of general formula (1), wherein the groups n, A, B, R1, R2 and R3 are defined as in the claims and in the description, and to methods for producing the same. The invention also relates to the use of...
|
|
WO/2005/107464A2 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.
|
|
WO/2005/108380A2 |
A process is provided which employs reactive controlled crystallization to produce drug substance having desirable crystal properties which process involves providing reactants A and B in liquid or solution form and adding reactant B to ...
|
|
WO/2005/107762A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2005/105764A1 |
Compounds of the formula (I): in which R, R1 and R2 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and . processes for the...
|
|
WO/2005/103020A1 |
The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as...
|
|
WO/2005/103012A1 |
Compounds represented by the general formula (I) and having cysteine protease inhibiting activity, salts, solvates, or N-oxides thereof, or prodrugs of them; and preventive and/or therapeutic agents for diseases in which cysteine proteas...
|
|
WO/2005/103017A1 |
A method for preparing a powder being improved in the rate of dissolution, characterized in that it comprises converting a slightly soluble drug having an acidic group (for example, 3-(5-&lcub 2-[5-methyl-2-(4-methylphenyl)-1,3-oxazole-4...
|
|
WO/2005/100318A1 |
The present invention relates to alkanoic acids and their derivatives, which have PPAR agonist activity, and hence can be used as antidiabetic compounds. Compounds disclosed herein can be used for the treatment of diabetes and diabetes-a...
|
|
WO/2005/100329A1 |
New protecting reagents are provided that allow for the selective placement of a new protecting group onto a reactive site of a multifunctional compound. The reagents are 2, 3, and 4-trialkylsilylxylyl, triarylsilylxylyl or a combination...
|
|
WO/2005/100334A1 |
The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R1 are as defined herein; phar...
|
|
WO/2005/099687A2 |
Disclosed herein are analogs of Salinosporamide A, having the Formulae Ia - IVa as follows: [insert chemical formula here] Like Salinosporamide A, the compounds of the present invention will inhibit the proteasome, an intracellular enzym...
|
|
WO/2005/097114A2 |
The present invention relates to compounds of the Formula (I) wherein R1, R2, R3, R4, m, n and p are as defined. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutica...
|
|
WO/2005/097765A1 |
The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. T...
|
|
WO/2005/097784A1 |
The invention relates to novel phenylthioacetic acid derivatives of formula (I), to a method for the production thereof, to the use thereof for the treatment and/or prophylaxis of diseases, in addition to the use thereof in the productio...
|
|
WO/2005/096734A2 |
Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
|
|
WO/2005/095363A1 |
A novel compound having excellent PPAR&agr /&gammad agonistic activity and having desirable properties required of medicines. It is a peroxisome proliferator-activated receptor &agr /&gammad agonist represented by the following general f...
|
|
WO/2005/095334A1 |
The present invention relates to compounds of the Formula (I), wherein R1, R2, R3, m, and n are as defined. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical com...
|
|
WO/2005/095365A1 |
The present invention relates to compounds of the Formula (I), wherein R1, R3, R5, R6 and R7 are as defined. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical co...
|
|
WO/2005/095364A1 |
A novel compound having excellent PPAR&agr /&gammad agonistic activity and having desirable properties required of medicines. It is a peroxisome proliferation-activated receptor &agr /&gammad agonist represented by the following general ...
|
|
WO/2005/095350A1 |
Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.
|
|
WO2004071447A9 |
This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising th...
|
|
WO/2005/092899A1 |
The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a metho...
|
|
WO/2005/092845A1 |
The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists...
|
|
WO/2005/090292A1 |
The invention relates to a compound having general formula (I), wherein: A is selected from among one or more X, Y and/or Z groups; X represents an optionally-substituted methylene group; Y represents a C2-alkenylene, optionally substitu...
|
